Essex Bio-Technology Limited

SEHK:1061 株式レポート

時価総額:HK$1.5b

Essex Bio-Technology 将来の成長

Future 基準チェック /06

現在、 Essex Bio-Technologyの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Biotechs 収益成長41.1%
収益成長率n/a
将来の株主資本利益率n/a
アナリストカバレッジ

None

最終更新日n/a

今後の成長に関する最新情報

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Oct 09
Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29
Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

May 06
Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Mar 21
Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Dec 07
Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 07
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Aug 25
Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Jun 22
Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02
Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30
Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31
Is Essex Bio-Technology (HKG:1061) A Risky Investment?

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13
If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15
How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25
Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04
Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23
Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Essex Bio-Technology は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:1061 - アナリストの将来予測と過去の財務データ ( )HKD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
6/30/20241,619263211316N/A
3/31/20241,663269211328N/A
12/31/20231,707275211339N/A
9/30/20231,634266169323N/A
6/30/20231,561256127307N/A
3/31/20231,439241113345N/A
12/31/20221,318225100383N/A
9/30/20221,437274103406N/A
6/30/20221,556323106430N/A
3/31/20221,597334130419N/A
12/31/20211,638346154409N/A
9/30/20211,515339124430N/A
6/30/20211,39233294451N/A
3/31/20211,18527532375N/A
12/31/2020978219-31299N/A
9/30/20201,00022113253N/A
6/30/20201,02222257207N/A
3/31/20201,15126257220N/A
12/31/20191,27930357233N/A
9/30/20191,23828232213N/A
6/30/20191,1972628194N/A
3/31/20191,18724653197N/A
12/31/20181,17623199201N/A
9/30/20181,100210119207N/A
6/30/20181,023189138214N/A
3/31/2018961178N/A204N/A
12/31/2017900167N/A194N/A
9/30/2017874159N/A166N/A
6/30/2017849151N/A138N/A
3/31/2017813144N/A114N/A
12/31/2016776136N/A90N/A
9/30/2016740126N/A63N/A
6/30/2016705115N/A37N/A
3/31/2016679110N/A53N/A
12/31/2015654105N/A69N/A
9/30/2015627101N/A75N/A
6/30/201560096N/A81N/A
3/31/201555986N/A58N/A
12/31/201451875N/A35N/A
9/30/201446667N/A43N/A
6/30/201441359N/A51N/A
3/31/201438057N/A58N/A
12/31/201334755N/A65N/A

アナリストによる今後の成長予測

収入対貯蓄率: 1061の予測収益成長が 貯蓄率 ( 2.3% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 1061の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 1061の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 1061の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 1061の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: 1061の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘